Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Bests Market Segment Report: Record Catastrophe Bond Issuance Boosts ILS Capacity and Reshapes Pricing Landscape
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Reinsurance pricing at the midyear 2025 renewals was the most…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
GMS Reports Fourth Quarter and Fiscal Year 2025 Results
Resilient Pricing Despite Challenging and Uncertain End Market Conditions; Additional Structural Cost…
Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color…